Successful initial results using cannabis terpenes to treat COVID-19

CBD News Aggregator – The Israeli in vivo study, carried out by Eybna and Cannasoul, is examining the efficacy of the unique cannabis terpene formulation – NT-VRL – in treating a diverse range of inflammatory conditions, including the life-threatening cytokine storm syndrome caused by COVID-19.

The early results from the study show that the terpene formulation combined with CBD, is twice as effective than CBD alone, and a common corticosteroids treatment for inflammation, Dexamethasone. The developers of the formulation say the results show that terpenes play an important medical role and are not just for flavour and fragrance.

Successful results treating inflammation

Cytokine storms impact cell communication and can both promote and deter inflammation – when released in large amounts they can cause multisystem organ failure. Recent studies have provided evidence that CBD may reduce cytokine storm and inflammation in COVID-19.

For this study, the compounds used in testing were the specially formulated Eybna NT-VRL, as well as CBD, and Dexamethasone as the positive control. The study, conducted on human peripheral blood mononuclear cells (PBMCs) from healthy donors, induced inflammation using lipopolysaccharide (LPS), and performed cytotoxicity tests prior to a cytokine storm experiment to ensure cell viability in the testing concentrations.

Leave a Reply